Exploring new treatment targets for neuropsychiatric symptoms in lupus
Potential of tissue kallikreins as therapeutic targets for neuropsychiatric lupus
['FUNDING_R21'] · TEMPLE UNIV OF THE COMMONWEALTH · NIH-10758599
This study is looking at how a specific protein might help improve mental health issues like anxiety and depression in people with lupus, by testing new oral medications in animals to see if they can reduce inflammation and improve symptoms.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TEMPLE UNIV OF THE COMMONWEALTH (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-10758599 on ClinicalTrials.gov |
What this research studies
This research investigates the role of tissue kallikreins in treating neuropsychiatric lupus, a condition that can cause anxiety, depression, and cognitive impairment in patients with systemic lupus erythematosus (SLE). The study focuses on how the kallikrein-kinin system can modulate the effects of interferon alpha, a common therapeutic agent that may contribute to depressive symptoms. By using animal models, researchers will assess the impact of oral medications that influence this system on neuroinflammation and related symptoms. The goal is to identify new therapeutic strategies that could improve mental health outcomes for lupus patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with systemic lupus erythematosus who are experiencing neuropsychiatric symptoms such as anxiety or depression.
Not a fit: Patients without a diagnosis of systemic lupus erythematosus or those not experiencing neuropsychiatric symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for neuropsychiatric symptoms in lupus patients, enhancing their quality of life.
How similar studies have performed: While the specific approach of targeting tissue kallikreins in neuropsychiatric lupus is novel, there is existing research indicating that modulation of the kallikrein-kinin system can influence inflammatory responses.
Where this research is happening
PHILADELPHIA, UNITED STATES
- TEMPLE UNIV OF THE COMMONWEALTH — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SRIRAM, UMA — TEMPLE UNIV OF THE COMMONWEALTH
- Study coordinator: SRIRAM, UMA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.